Skip to Content

Alcon Inc ALC

Morningstar Rating
CHF 80.86 −1.42 (1.73%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Alcon Earnings: Starts 2024 on a Strong Note From Healthy Consumer Demand and Market Penetration

Narrow-moat Alcon reported strong first-quarter earnings that came in above our expectations. Total sales of $2.5 billion were up 5%, or 7% in constant currencies year over year, and margins showed a nice recovery. Healthy demand, pricing, and trade-ups buoyed sales with minor offsets from unfavorable foreign exchange headwinds. After updating our model, we maintain our fair value estimate of $70 (CHF 62) per share as impacts from our adjustments were too minor to move our valuation.

Price vs Fair Value

ALC is trading at a 639% premium.
Price
CHF 80.86
Fair Value
CHF 88.00
Uncertainty
Medium
1-Star Price
CHF 53.70
5-Star Price
CHF 36.80
Economic Moat
Svmvqfc
Capital Allocation
Nyfmjzpd

Bulls Say, Bears Say

Bulls

Alcon is one of the leading visioncare companies in the world, with a record of successful product development, and it will continue to launch technically superior products.

Bears

A failure to help doctors transition from Centurion to a new phacoemulsification machine (upon launch in the next two years) could leave some customers unsatisfied and moving to a different manufacturer.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CHF 82.28
Day Range
CHF 80.8482.58
52-Week Range
CHF 61.2883.34
Bid/Ask
CHF 80.60 / CHF 0.00
Market Cap
CHF 39.88 Bil
Volume/Avg
904,000 / 917,176

Key Statistics

Price/Earnings (Normalized)
29.92
Price/Sales
4.82
Dividend Yield (Trailing)
0.29%
Dividend Yield (Forward)
0.29%
Total Yield
0.29%

Company Profile

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Growth
Total Number of Employees
25,315

Competitors

Valuation

Metric
ALC
COO
AFX
Price/Earnings (Normalized)
29.9227.5830.25
Price/Book Value
2.162.373.94
Price/Sales
4.824.993.99
Price/Cash Flow
23.3021.1825.37
Price/Earnings
ALC
COO
AFX

Financial Strength

Metric
ALC
COO
AFX
Quick Ratio
1.310.812.34
Current Ratio
2.511.863.51
Interest Coverage
5.864.7719.18
Quick Ratio
ALC
COO
AFX

Profitability

Metric
ALC
COO
AFX
Return on Assets (Normalized)
4.73%2.49%
Return on Equity (Normalized)
6.76%3.88%
Return on Invested Capital (Normalized)
5.92%3.63%
Return on Assets
ALC
COO
AFX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncNjhvnwxlzYypk$143.6 Bil
BDX
Becton Dickinson & CoHyvsmgykrNtrpcv$66.1 Bil
ALC
Alcon IncYlvmzrdjlXljvbf$44.4 Bil
RMD
ResMed IncQszpsdfxPbnvjxs$31.3 Bil
CLPBY
Coloplast A/S ADRFcwrdgspzNzzm$28.1 Bil
WST
West Pharmaceutical Services IncTklbdlfxcjHnhk$24.3 Bil
COO
The Cooper Companies IncYcyjpvswlNksmzq$18.2 Bil
BAX
Baxter International IncKjhbvlcHrwfgt$17.3 Bil
HOLX
Hologic IncXjsstzyXwdqgq$17.2 Bil
ATR
AptarGroup IncMhbpqnmzwZgyrsd$9.8 Bil

Sponsor Center